Eli Lilly and Company (NYSE: LLY), a global healthcare company, has announced results from a comparative study on its once-weekly insulin efsitora alfa. The study demonstrated that efsitora alfa is non-inferior in reducing A1C levels compared to daily basal insulins degludec or glargine in adults with type 2 diabetes (T2D). The observed benefit was consistent across patients, regardless of their history of insulin or GLP-1 receptor agonist use.
Furthermore, Lilly’s insulin candidate efsitora alfa showed an acceptable safety and tolerability profile, which is crucial for its potential use in diabetes management.- Flcube.com